{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 64,
  "pageCount": 415,
  "prevPage": 63,
  "nextPage": 65,
  "slideType": "nominee_bio",
  "function": "introduce_nominees",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "The slide uses direct quotes from an expert to undermine the commercial viability and clinical efficacy of the drug.",
  "elementsJson": [
    "headline_text",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/64",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-64",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Lack of patient enthusiasm since Vykat FDA approval, with only 3 families calling out of >40 total: \"I got three calls...so no, it wasn't a floodgate that opened.\"",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29b-220434fa94c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.71
      },
      "kind": "list",
      "text": "Stated that only 1 out of approximately 10 trial enrollees even responded to Vykat and even that patient was barely a responder: “well, one [patient]...and I wouldn't call it a wow response.” Even more damning, this “effect” was observed after the patient “must been on it at least a year and a half by that point” - a dubious response given the highly subjective and unreliable hyperphagia questionnaire.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07099df6-13f8-4985-8a0a-c9a393cbf612",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.28
      },
      "kind": "list",
      "text": "Involved in the Vykat phase 3, open-label, and withdrawal studies and indicated a massive patient discontinuation rate with only 2 of ~10 enrollees still remaining on drug, due to serious adverse effects, continued weight gain, and/or lack of effect.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a156846-f0a0-4f10-a68f-bdbc5a8c88e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.86,
        "x": 0.07,
        "y": 0.84
      },
      "kind": "list",
      "text": "Stated Vykat is not a blockbuster drug and is only “trying it” here and there because “we have nothing else.” The investigator indicated that other physicians “who are in town are, I think, very unlikely to go prescribing on their own...they're probably going to ask me to do it.” We note the investigator is in a large metro area in a major state.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d4b3ffb-d1b0-431f-8497-1b5efbdc8a39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.86,
        "x": 0.07,
        "y": 0.6
      },
      "kind": "list",
      "text": "Not reaching out to patients to put them on Vykat, but is willing to submit start forms for those who insist - 3 forms submitted to date, with one approval, one denial, and one in a black hole: “I'm not reaching out to people proactively...I'm letting them reach out to me and a couple have...because they are following the story.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8dc334ca-b0da-4550-92dd-f70b2cade81d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.41
      },
      "kind": "list",
      "text": "Lack of patient enthusiasm since Vykat FDA approval, with only 3 families calling out of >40 total: “I got three calls...so no, it wasn't a floodgate that opened.” The investigator noted similar dismissiveness in the collaborative of PWS specialists with the largest patient caseloads in the US: “I wouldn't say anybody is wildly over the moon...it's not like a miracle...I don't think anybody's used the term miraculous to describe that they're seeing...no, it's not a cure.”",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df8f88f7-c30f-4217-a342-f77baf931e80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"I wouldn't say anybody is wildly over the moon...it's not like a miracle...I don't think anybody's used the term miraculous to describe that they're seeing...no, it's not a cure.\" — Trial investigator #5",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29b-267bdb827f5b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c874925-3dea-4f0f-8aaa-e5ae90126441",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #5: Influential key opinion leader with >40 PWS patients currently and 100-150 historically. A large enroller in the Vykat trials and co-author on the papers. Follows a larger group of PWS patients nationally and is a member of a collaborative of 25-35 leading PWS practitioners who manage ~25% of all patients in the US – “they all each have 50 or so patients they follow.”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "575c3901-ead1-4dab-a1f4-8ea4828b779c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}